Department of Surgery, University Hospital, S 70185 Orebro, Sweden.
Eur J Vasc Endovasc Surg. 2010 Sep;40(3):375-80. doi: 10.1016/j.ejvs.2010.05.005. Epub 2010 Jun 15.
To briefly inform on the conclusions from a conference on the next 10 years in the management of peripheral artery disease (PAD).
International participation, invited presentations and open discussion were based on the following issues: Why is PAD under-recognised? Health economic impact of PAD; funding of PAD research; changes of treatment options? Aspects on clinical trials and regulatory views; and the role of guidelines.
A relative lack of knowledge about cardiovascular risk and optimal management of PAD patients exists not only among the public, but also in parts of the health-care system. Specialists are required to act for improved information. More specific PAD research is needed for risk management and to apply the best possible evaluation of evidence for treatment strategies. Better strategies for funding are required based on, for example, public/private initiatives. The proportion of endovascular treatments is steadily increasing, more frequently based on observational studies than on randomised controlled trials. The role of guidelines is therefore important to guide the profession in the assessment of most relevant treatment.
简要介绍一次关于未来 10 年外周动脉疾病（PAD）管理的会议的结论。
国际参与、特邀演讲和公开讨论基于以下问题：为什么 PAD 被低估了？PAD 的健康经济影响；PAD 研究的资金；治疗选择的变化？临床试验和监管观点的各个方面；以及指南的作用。
不仅公众，而且医疗保健系统的某些部分，对心血管风险和 PAD 患者的最佳管理都知之甚少。需要专家采取行动以提高信息传播。需要更具体的 PAD 研究来进行风险管理，并应用最佳的证据评估治疗策略。需要根据公共/私人倡议等制定更好的资金策略。血管内治疗的比例稳步增加，更多地基于观察性研究而不是随机对照试验。因此，指南的作用对于指导专业人员评估最相关的治疗方法非常重要。
